The global biliary atresia treatment market size was valued at USD 910 million in 2021 and is projected to reach around USD 1,600 million in 2030 exhibiting a CAGR of 8.0% in the forecasted period. The availability of advanced treatment procedures, increase in the number of research and development activities are expected to upsurge the market growth. Moreover, the strategic initiatives and collaborations is also predicted to boost the market. However, complications of biliary atresia drugs, unavailability of suitable treatments are hampering the growth of the market in the forecasted period.
Organizations' multiple determinations to design and carry out revisions on rare diseases are anticipated to help in the growth of the global biliary atresia treatment market during the forecasted period. For instance, an organization named as ‘The Childhood Liver Disease Research Network’ (children) is a cooperative team of nurses, medical facilities, doctors, research coordinators, and patient support organizations. These vast organization intends to develop the lives of young people and families suffering from unusual liver diseases. The Children Network was initiated in October 2019, to support the discovery of the latest etiologic, diagnostic, treatment selections for children with liver disease, and people who experience liver transplantation. All these aspects are also contributing in the growth of the market.
COVID-19 has left a major global public health crisis that made an impact almost every business and a heavy impact on the global biliary atresia treatment market. The COVID-19 pandemic has certainly had a great impact on study and clinical trials of biliary atresia. They have been tremendously impacted due to the enormous lack of new sample collections. Moreover, as per the article issued by American Association for the Study of Liver Diseases, substantial decline in donations with unmatched financial trials and the termination of all fundraising events, will definitely impact paediatric liver research funding. But, on a positive note, the COVID-19 disease has supported the paediatric hepatology community. For example, there is an association called The Society of Pediatric Liver Transplantation–The Transplantation Society and North American Society for Pediatric Gastroenterology, Hepatology & Nutrition has initiated a joint national registry for COVID-19 in kids with post–liver transplantation and chronic liver disease.
During the pandemic, several hospitals have decided to cancel or suspend other processes. Post pandemic, the situation upgraded a bit and doctors and physicians could emphasise on the other syndromes, comprising these rare syndromes. Travel limitations has uplifted and handlings are expanding at a high pace. Telemedicine in terms of genetic treatment are also on the increase and is really helpful, specifically for treating these kind of illnesses.
Disease Type Insights
Based on the disease type, the biliary atresia treatment market is categorized into Type I, Type II, and Type III. In 2021, the type III segment ruled the market with the largest market share of around 37%. Because of the comparatively high prevalence of type III biliary atresia, the type III segment is projected to have the biggest market share in the global biliary atresia treatment market throughout the forecasted period. For instance, type III, also called as porta hepatis, is said to influence around 85–90% of individuals detected with biliary atresia, as specified in an article by Science Direct published in 2016.
Treatment Type Insights
Based on treatment type, the biliary atresia treatment market is categorized into medications, bile acids analogues, antibiotics, corticosteroids, and others. In 2021, antibiotics led the market with the largest market share of 28%. The antibiotic method is the primary treatment for biliary atresia as there is no known cure for this disease. Antibiotic medication is used widely during the Kasai procedure, anticipated to drive the segment’s growth.
Region Insights
In 2021, North America emerged as the largest market for the global biliary atresia treatment market, with a market share of around 36%. The market for biliary atresia treatment is enhancing due to augmented R&D activities. Individuals in North America are very much conscious of biliary atresia, which is also a factor in boosting the market's growth in the region. Additionally, the growing awareness about biliary atresia treatment and innovative healthcare facilities in the region propel the growth of the market.
The Asia Pacific market is projected to grow at the fastest CAGR. The market for biliary atresia treatment in the Asia Pacific region has been increasing due to the growing government initiatives and the high prevalence rate of biliary atresia. The rising demand for the treatment of biliary atresia is becoming a purpose for the growth of the biliary atresia market in Asia- Pacific. There is also a development in the efficient medical devices in the region along with the growing interest of people in taking care of ageing people at home with easy & simple products.
Key Companies Insights
The market for biliary atresia treatment is moderately competitive. With the rising applications of Biliary atresia treatment, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the biliary atresia treatment market, ultimately boosting the market growth. Some of the key companies working in the global biliary atresia treatment market include:
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Pfizer Inc.
• Novartis AG
• AstraZeneca
• Johnson & Johnson Private Limited
• Sun Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Amgen Inc.
• Merck KGaA
• Beckman Coulter Inc.
• Glenmark Pharmaceuticals Inc.
• Amneal Pharmaceuticals LLC
• Other players
Some of the Recent Developments:
• In October 2021, pentoxifylline (PTX), is over phase II of clinical trials. The aim of the trial is to establish whether or not PTX holds a level of biological activity against biliary atresia.
• In September 2021, Maralixibat (LIVMARLI) is in phase 2b of its clinical study for juvenile liver illnesses called as biliary atresia. This experiment is being shown to determine the treatment’s efficiency.
Segments
By Disease Type
• Type I
• Type II
• Type III
By Treatment Type
• Medications
• Bile Acids
• Antibiotics
• Corticosteroids
• Surgery
By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt